Stered in PROSPERO, the international prospective register of systematic evaluations (CRD #42020168084), available at: https://www.crd.york.ac.uk/PROSPERO.Ontario Health Technologies Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugustMMP-12 Inhibitor review clinical EvidenceResearch QuestionWhat may be the clinical utility of multi-gene pharmacogenomic testing that contains decision-support tools to guide medication choice compared with therapy as usual for men and women with main depressionMethods Clinical Literature SearchWe performed a clinical literature search on January 24, 2020, to retrieve studies published from database inception until the search date. We made use of the Ovid interface in the following databases: MEDLINE, Embase, the Cochrane Central Register of Controlled PI3K Inhibitor custom synthesis trials, the Cochrane Database of Systematic Reviews, the Wellness Technologies Assessment database, along with the National Well being Service Financial Evaluation Database (NHS EED), and PsycINFO. A medical librarian developed the search approaches making use of controlled vocabulary (e.g., Healthcare Topic Headings) and relevant keywords and phrases. The final search method was peer reviewed working with the PRESS Checklist.40 We made database auto-alerts in MEDLINE, Embase, and PsycINFO, and monitored them for the duration in the assessment period. We also performed a targeted grey literature search of wellness technology assessment agency websites too as clinical trial and systematic review registries. See Appendix 1 for our literature search strategies, which includes all search terms.Eligibility CriteriaSTUDIES Inclusion CriteriaEnglish-language full-text publications Studies published from database inception till January 24, 2020 Randomized controlled trials, non-randomized studies, systematic critiques, and meta-analysesExclusion CriteriaAnimal and in vitro research Non-systematic critiques, narrative evaluations, abstracts, editorials, letters, case reports, and commentaries Unpublished data, draft information, and manuscripts Gene discovery, analytical validity, and clinical validity research Non-comparative studies (e.g., non-comparative just before fter cohort studies)Ontario Overall health Technologies Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugust 2021 PARTICIPANTS Inclusion CriteriaAdults (aged 18 years and over) having a principal diagnosis of major depression requiring pharmacological remedy o Studies with combined populations had been integrated only if results for the depression subgroup could be extractedSubpopulations o o Medication-naive (initiating pharmacological remedy) Inadequate response to one or more medications (i.e., lack of clinical improvement, unable to tolerate treatment, or created unwanted effects)Exclusion CriteriaBipolar depression Young children and adolescentsINTERVENTIONS Inclusion CriteriaMulti-gene (two or extra genes) pharmacogenomic tests that involve a clinical decision-support tool to guide depression medication selection o Decision-support tools defined as selection of medication or dosage suggestions or guidanceExclusion CriteriaSingle-gene tests Tests that do not give medication or dosage recommendationsCOMPARATORS Inclusion CriteriaNo pharmacogenomic testing to guide depression medication choice or dose adjustment (remedy as usual)Exclusion CriteriaStudies comparing distinctive pharmacogenomic tests or genesOntario Overall health Technologies Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugust 2021 OUTCOME MEASURESChange in depression outcomes o o o o o o Alter in depression scores (e.g., HAM-D17); a minimally c.